查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924632

血库市场按产品类型、最终用户、采集方法、应用和技术划分－2026-2032年全球预测

Blood Bank Market by Product Type, End User, Collection Method, Application, Technology - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，血液银行市场价值将达到 107.9 亿美元，到 2026 年将成长到 116.3 亿美元，到 2032 年将达到 204.1 亿美元，年复合成长率为 9.52%。

关键市场统计数据
基准年 2025 107.9亿美元
预计年份：2026年 116.3亿美元
预测年份 2032 204.1亿美元
复合年增长率 (%) 9.52%

一个将整个医疗系统的经营团队重点与临床需求、营运韧性和技术进步连结起来的血库生态系统策略框架

血库产业正处于策略转折点，临床需求、技术创新和日益严格的监管压力正在重新定义血液製品的采集、加工和分发方式。本文阐述了领导者需要了解的关键营运、科学和商业动态，以应对短期衝击和实现长期转型。文章重点分析了供应链韧性、产品差异化以及医院系统、诊断中心和研究机构等各相关人员期望之间的相互作用，从而为相关问题提供了背景。

对于医疗保健领域的领导者而言，技术、临床和监管力量的融合正在重塑血库的营运、供应策略和品管重点。

血液库环境正经历变革性的转变，这主要受技术成熟、临床实践发展和监管力度加大的推动。自动化处理平台和就地检验的日益普及，已开始重塑检查室工作流程，从而加快结果报告速度并提高标准化程度。同时，捐血筛检和病原体减少技术的进步，提高了安全裕度，迫使检查室和供应商重新评估资金配置和供应商伙伴关係。

了解不断变化的关税政策如何影响整个血库供应链的筹资策略、来源多元化和协作紧急时应对计画。

美国近期关税调整对血库产业的供应链、筹资策略和跨境伙伴关係产生了连锁反应。部分试剂、医疗抛弃式产品和低温运输设备的关税上调，导致许多营运投入品的到岸成本增加，迫使采购团队重新评估筹资策略，并探索替代供应商和近岸外包方案。因此，各机构不得不权衡成本压力与产品安全和临床供应不间断这一不可妥协的需求。

透过细分市场分析，将血液服务生态系统中产品、最终用户、采集方法、应用和技术方面的差异映射到客製化的营运和商业策略。

透过精准的市场区隔观点，我们可以发现每种产品类型、最终用户、采集方法、应用领域和技术都检验不同的营运和商业影响。例如，冷沉淀、新鲜冷冻血浆和冷冻血浆、单采或混合血小板、去白血球或洗涤红血球以及全血等产品类型，在加工需求、储存限制和临床应用模式方面存在显着差异，从而导致各自独特的供应链和品管需求。

从区域观点，将美洲、欧洲、中东和非洲以及亚太地区的营运重点与基础设施、法规和临床需求连结起来。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的营运模式、监管方式和伙伴关係机会的形成至关重要。在美洲，一体化的医院系统和大规模区域血液网络推动了集中筹资策略和健全的物流体系。同时，法规环境强调严格的品管和可追溯性，影响各机构如何建构其库存和捐血计画。区域内的跨境合作也为特殊成分的紧急时应对计画提供了支持。

竞争定位、技术合作和服务差异化如何影响血液银行价值链中供应商的策略和采购偏好？

血库生态系统内的竞争格局揭示出，专业供应商、平台提供者和临床服务机构正竞相投资产品差异化、服务商品搭售和技术整合。领先的仪器製造商和试剂供应商正在拓展产品组合，纳入整合自动化解决方案、软体支援的库存管理和数据分析服务，以帮助检查室减少人工操作并提高合规性。同时，临床服务供应商透过保证服务品质、快速反应能力和区域配送网路来确保关键组件的及时供应，从而实现差异化竞争。

为领导者提供切实可行的、优先排序的行动指南，以增强韧性、协调临床和筹资策略，并加速血库采用以价值主导的技术。

产业领导者应制定一系列切实可行的优先事项，以平衡即时营运稳定与中期策略转型。首先，选择性地投资于自动化和数位化可追溯性项目，以直接降低人为错误率并提高库存可见性，并分阶段实施，以避免对核心临床服务造成干扰。其次，透过供应商多元化、灵活的合约谈判（考虑关税波动）以及尽可能评估近岸製造方案，增强采购韧性。

本研究采用混合方法，结合专家的直接访谈和系统性的第二手资料分析，以确保对血库运作和策略有严谨、实用的见解。

本分析的调查方法结合了针对性的初步研究和严谨的二次分析，以确保其可靠性和相关性。初步数据包括对临床负责人、输血医学专业人员、血站管理人员和采购负责人的结构化访谈，旨在了解当地的营运挑战、技术应用障碍和策略重点。这些访谈旨在检验假设、探索新的应用案例，并揭示不同地区工作流程和供应动态的差异。

一份简洁而全面的分析报告，强调了在血液服务领域实现弹性运作、技术赋能的工作流程以及伙伴关係主导的改进的战略必要性。

总之，血库产业目前正经历一场意义深远的变革时期，临床发展、技术进步和供应链动态的交汇融合，既带来了挑战，也带来了机会。采取策略性策略，优先推动目标自动化、强化采购和加强临床协作的机构，将更有利于确保医疗服务的连续性，并提高营运效率。同样重要的是，需要建立健全的资料管治、加强人才培养，并具备在地化适应能力，以维持高品质的服务交付。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的血库市场

  • 冷沉淀物
  • 电浆
    • 新鲜冷冻血浆
    • 冷冻血浆
  • 血小板
    • 血小板分离术
    • 混合血小板
  • 红血球
    • 白血球耗竭的红血球
    • 洗涤过的红血球
  • 全血

第九章 依最终用户分類的血库市场

  • 血库
  • 诊所
  • 诊断中心
  • 医院
  • 研究所

第十章：以采集方式分類的血库市场

  • 血液分离术
  • 全血

第十一章 依应用分類的血库市场

  • 诊断
  • 研究
  • 输血

第十二章 科技驱动的血库市场

  • 自动化
  • 手动的
  • 护理点

第十三章 各地区的血库市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 血库市场（以血库集团划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国血库市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国血库市场

第十七章：中国血库市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Blood Bank Computer Systems
  • Cordlife Group Limited
  • Cryo-Cell International, Inc.
  • Danaher Corporation
  • FamiCord Group
  • Fresenius SE & Co. KGaA
  • GE Healthcare
  • Grifols, SA
  • Haemonetics Corporation
  • Hoffmann-La Roche AG
  • J Mitra & Company Pvt. Ltd.
  • Johnson & Johnson
  • Macopharma SAS
  • MAK-SYSTEM
  • MedTech Solutions
  • Medtronic plc
  • Nipro Corporation
  • Oracle Corporation
  • Terumo Corporation
  • WellSky Corporation
Product Code: MRR-7A380DA7C3E7

The Blood Bank Market was valued at USD 10.79 billion in 2025 and is projected to grow to USD 11.63 billion in 2026, with a CAGR of 9.52%, reaching USD 20.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.79 billion
Estimated Year [2026] USD 11.63 billion
Forecast Year [2032] USD 20.41 billion
CAGR (%) 9.52%

A strategic framing of the blood bank ecosystem that ties clinical demand, operational resilience, and technological progress to executive priorities across healthcare systems

The blood bank environment is at a strategic inflection point where clinical demand, technological innovation, and regulatory rigor converge to redefine how blood products are collected, processed, and distributed. This introduction frames the critical operational, scientific, and commercial dynamics that leaders must understand to navigate short-term disruptions and long-term transformation. It sets the stage by highlighting the interplay between supply chain resilience, product differentiation, and stakeholder expectations across hospital systems, diagnostic centers, and research institutions.

Over recent years, advances in automation, donor screening technology, and inventory management have reduced variability while increasing throughput, yet persistent challenges remain in donor recruitment, cold chain integrity, and equitable access to specialized components such as platelets and cryoprecipitate. Consequently, executives are being asked to reconcile clinical imperatives with cost containment, regulatory compliance, and evolving reimbursement models. This broader context underscores why operational excellence and strategic foresight are essential for maintaining continuity of care.

Drawing on a synthesis of technical developments and operational lessons, this introduction prepares readers to examine subsequent sections that explore structural shifts, policy impacts, segmentation-driven opportunities, and regional dynamics. By grounding the discussion in pragmatic realities rather than speculative projections, the text equips decision-makers with a clear lens for prioritizing investments, partnerships, and process improvements across the blood bank ecosystem.

How converging technological, clinical, and regulatory forces are reshaping blood bank operations, supply strategies, and quality management priorities for healthcare leaders

The landscape of blood banking is undergoing transformative shifts driven by technological maturation, evolving clinical practices, and heightened regulatory scrutiny. Increasing adoption of automated processing platforms and point of care testing has begun to reshape laboratory workflows, enabling faster turnaround times and improved standardization. At the same time, advancements in donor screening and pathogen-reduction technologies are enhancing safety margins, prompting laboratories and suppliers to reassess capital allocation and vendor partnerships.

Simultaneously, clinical practice trends are altering demand profiles for specific blood components. Precision transfusion strategies and tighter transfusion thresholds have elevated the importance of component optimization, while growth in complex surgeries and aging populations sustains demand for specialized products such as leukoreduced and washed red blood cells. These clinical drivers intersect with logistics innovations, including just-in-time inventory models and digital cold-chain monitoring, which together improve availability while reducing wastage.

Regulatory pressures and quality frameworks are also reshaping operational priorities. Laboratories and collection centers are investing in robust traceability systems and data governance to meet inspection readiness and to facilitate rapid product recalls when necessary. As a result, organizations that proactively integrate technological capabilities with process redesign and workforce upskilling will be best positioned to capitalize on these transformative shifts and to deliver resilient, high-quality blood services across care settings.

Understanding how evolving tariff policies are driving procurement strategies, supplier diversification, and collaborative contingency planning across the blood bank supply chain

Recent tariff changes in the United States have created a ripple effect across supply chains, procurement strategies, and cross-border partnerships in the blood bank sector. Increased duties on certain reagents, medical disposables, and cold-chain equipment have amplified landed costs for many operational inputs, prompting procurement teams to reassess sourcing strategies and to explore alternative suppliers or nearshoring options. Consequently, organizations are balancing cost pressures against the non-negotiable needs of product safety and uninterrupted clinical supply.

These trade adjustments have also heightened the importance of transparent supplier agreements and long-term contracting to stabilize input costs. Procurement functions are working more closely with clinical leadership to prioritize critical items and to adjust inventory policies where clinically acceptable. In parallel, vendors are responding by diversifying manufacturing footprints and offering bundled services that can mitigate tariff exposure, such as localized assembly or service contracts that reduce the need for cross-border goods movement.

Importantly, the cumulative effects of tariffs have encouraged collaborative responses among healthcare providers, regional blood networks, and manufacturers to develop contingency plans that preserve patient care continuity. Strategic initiatives now emphasize supply chain visibility, scenario planning, and contractual flexibility so that clinical operations remain insulated from sudden policy or cost fluctuations while still maintaining compliance and product integrity.

A segmented analysis that maps product, end-user, collection, application, and technology distinctions to tailored operational and commercial strategies across the blood services ecosystem

Disaggregating the market through a precise segmentation lens reveals differentiated operational and commercial implications across product types, end users, collection methods, applications, and technologies. When examining product types such as cryoprecipitate, plasma in its fresh frozen and frozen variants, platelets available as apheresis or pooled units, red blood cells offered as leukoreduced or washed products, and whole blood, it becomes clear that processing requirements, storage constraints, and clinical utilization patterns vary considerably, driving distinct supply chain and quality management needs.

End users including blood banks, clinics, diagnostic centers, hospitals, and research institutes each bring unique demand signals and service level expectations. Blood banks orchestrate collection and distribution while hospitals and clinics focus on point-of-care readiness. Diagnostic centers and research institutes prioritize sample integrity and traceability for testing and experimental applications. Collection methods, whether apheresis or whole blood, further shape operational workflows, donor recruitment strategies, and equipment investments, as apheresis enables targeted component collection while whole blood collection supports broader inventory flexibility.

Application categories such as diagnostic use, research purposes, and transfusion therapy determine handling protocols and regulatory oversight. Meanwhile, technology choices-automated platforms, manual processes, and point of care solutions-influence throughput, error rates, and capital expenditure profiles. Taken together, these segmentation dimensions provide a framework for tailoring clinical protocols, infrastructure investments, and commercial engagement strategies in ways that align with operational priorities and patient-centered outcomes.

A regionally informed perspective that connects infrastructure, regulation, and clinical demand across Americas, Europe Middle East & Africa, and Asia-Pacific to operational priorities

Regional dynamics are pivotal in shaping operational models, regulatory approaches, and partnership opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated hospital systems and large regional blood networks drive centralized procurement strategies and robust logistics frameworks, while the regulatory environment emphasizes stringent quality control and traceability, influencing how organizations structure inventory and donor programs. Cross-border collaboration within the region also supports contingency planning for specialized components.

Europe, Middle East & Africa presents a mosaic of regulatory regimes and infrastructure maturity, where national policies and regional harmonization efforts influence donor engagement models and distribution networks. Investment priorities often include upgrading cold-chain capabilities and standardizing testing protocols to mitigate variability and to support equitable access across urban and rural areas. In the Asia-Pacific region, rapid modernization of healthcare infrastructure, a growing base of tertiary care facilities, and expanding research activity are increasing demand for advanced component processing and automation, even as supply challenges and donor mobilization remain focal concerns.

Together, these regional characteristics underscore the importance of geographically informed strategies that balance centralized capabilities with localized execution. By aligning technology adoption, workforce development, and partnership frameworks to regional strengths and constraints, organizations can enhance resilience, improve patient outcomes, and capture strategic advantages in their respective markets.

How competitive positioning, technology partnerships, and service differentiation are shaping supplier strategies and procurement preferences across the blood bank value chain

Competitive dynamics within the blood bank ecosystem reveal a mix of specialized suppliers, platform providers, and clinical service organizations that are investing in product differentiation, service bundling, and technological integration. Leading device manufacturers and reagent suppliers are expanding their portfolios to include integrated automation solutions, software-enabled inventory management, and data analytics services that help laboratories reduce manual steps and improve compliance. At the same time, clinical service providers are differentiating through quality-of-service commitments, rapid response capabilities, and regional distribution networks that support timely access to critical components.

Partnerships between technology vendors, blood centers, and healthcare systems are becoming more strategic, focusing on interoperability, digital traceability, and workflow optimization. Companies that can demonstrate validated clinical benefits, lower total cost of ownership, and scalable implementation pathways tend to be favored in procurement evaluations. Moreover, smaller niche providers continue to innovate in specialized segments such as pathogen reduction, advanced donor screening assays, and component-specific storage solutions, creating avenues for collaboration and acquisition by larger firms seeking to broaden their clinical utility.

Overall, competitive positioning in this landscape hinges on the ability to couple robust product performance with strong service models, regulatory support, and data-driven outcomes. Vendors and service organizations that prioritize customer-centric implementation, long-term training, and outcomes measurement will be better positioned to secure sustained engagement from hospitals, blood networks, and research institutions.

Practical and prioritized actions for leaders to strengthen resilience, align clinical and procurement strategies, and accelerate value-driven technology adoption in blood banking

Industry leaders should pursue a set of actionable priorities that balance immediate operational stabilization with medium-term strategic transformation. First, invest selectively in automation and digital traceability initiatives that directly reduce manual error rates and enhance inventory visibility, while sequencing implementation to avoid disruption to core clinical services. Next, strengthen procurement resilience by diversifying suppliers, negotiating flexible contracts that account for tariff volatility, and evaluating nearshore manufacturing options where feasible.

In addition, adopt a clinical alignment approach that integrates transfusion stewardship with product lifecycle management, ensuring that clinical teams are engaged in demand forecasting, component utilization reviews, and supply optimization. Workforce development is equally critical: implement targeted training programs to upskill lab personnel on new platforms and quality systems, and create cross-functional teams to manage change. Strategic partnerships with technology vendors should emphasize interoperability, outcome validation, and shared implementation risk to accelerate adoption while preserving clinical assurance.

Finally, prioritize data governance and analytics capabilities that enable proactive quality oversight, traceability, and performance measurement. By linking operational metrics with clinical outcomes, organizations can make evidence-based investment decisions, reduce wastage, and demonstrate value to payers and institutional stakeholders. Taken together, these actions will help organizations maintain continuity of care while advancing toward more efficient, technology-enabled models of blood services provision.

A mixed-methods approach blending primary expert interviews and systematic secondary synthesis to ensure rigorous, actionable insights into blood bank operations and strategy

The research methodology underpinning this analysis combined targeted primary inquiry with rigorous secondary synthesis to ensure robustness and relevance. Primary inputs included structured interviews with clinical leaders, transfusion medicine specialists, blood center executives, and procurement professionals to capture frontline operational challenges, technology adoption barriers, and strategic priorities. These interviews were designed to validate hypotheses, explore emerging use cases, and surface region-specific nuances in workflows and supply dynamics.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance, technical white papers, and vendor documentation to map technological capabilities, quality frameworks, and process standards. The analysis employed data triangulation to reconcile differing perspectives and to identify consistent patterns across sources. Where possible, case examples and implementation anecdotes were used to illustrate practical lessons and to highlight scalable best practices.

Quality assurance steps included expert review cycles, methodologic transparency, and iterative refinement of findings in response to stakeholder feedback. This mixed-methods approach provided a balanced view of operational realities and strategic opportunities, enabling conclusions and recommendations that are grounded in both empirical observation and technical plausibility.

A concise synthesis that reinforces the strategic imperatives for resilient operations, technology-enabled workflows, and partnership-driven improvements across blood services

In conclusion, the blood bank sector is navigating a period of meaningful change in which clinical evolution, technological progress, and supply chain dynamics converge to create both challenges and opportunities. Organizations that adopt a strategic posture-prioritizing targeted automation, procurement resilience, and clinical alignment-will be better able to ensure continuity of care and to realize efficiency gains. Equally important is the need for robust data governance, workforce development, and regional adaptability to sustain high-quality service delivery.

As stakeholders respond to tariff pressures, regulatory expectations, and shifting demand profiles for specific components, collaborative models and technology-enabled workflows will become increasingly central to operational success. By focusing on validated outcomes, interoperable solutions, and scalable implementation strategies, leaders can navigate near-term disruptions while building durable capabilities that support patient-centered transfusion care. The path forward demands disciplined investment, pragmatic partnerships, and continuous performance measurement to translate innovation into measurable clinical and operational value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Bank Market, by Product Type

  • 8.1. Cryoprecipitate
  • 8.2. Plasma
    • 8.2.1. Fresh Frozen Plasma
    • 8.2.2. Frozen Plasma
  • 8.3. Platelets
    • 8.3.1. Apheresis Platelets
    • 8.3.2. Pooled Platelets
  • 8.4. Red Blood Cells
    • 8.4.1. Leukoreduced Red Blood Cells
    • 8.4.2. Washed Red Blood Cells
  • 8.5. Whole Blood

9. Blood Bank Market, by End User

  • 9.1. Blood Banks
  • 9.2. Clinics
  • 9.3. Diagnostic Centers
  • 9.4. Hospitals
  • 9.5. Research Institutes

10. Blood Bank Market, by Collection Method

  • 10.1. Apheresis
  • 10.2. Whole Blood

11. Blood Bank Market, by Application

  • 11.1. Diagnostic
  • 11.2. Research
  • 11.3. Transfusion

12. Blood Bank Market, by Technology

  • 12.1. Automated
  • 12.2. Manual
  • 12.3. Point Of Care

13. Blood Bank Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Blood Bank Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Blood Bank Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Blood Bank Market

17. China Blood Bank Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Asahi Kasei Corporation
  • 18.7. B. Braun Melsungen AG
  • 18.8. Becton, Dickinson and Company
  • 18.9. Bio-Rad Laboratories, Inc.
  • 18.10. Blood Bank Computer Systems
  • 18.11. Cordlife Group Limited
  • 18.12. Cryo-Cell International, Inc.
  • 18.13. Danaher Corporation
  • 18.14. FamiCord Group
  • 18.15. Fresenius SE & Co. KGaA
  • 18.16. GE Healthcare
  • 18.17. Grifols, S.A.
  • 18.18. Haemonetics Corporation
  • 18.19. Hoffmann-La Roche AG
  • 18.20. J Mitra & Company Pvt. Ltd.
  • 18.21. Johnson & Johnson
  • 18.22. Macopharma SAS
  • 18.23. MAK-SYSTEM
  • 18.24. MedTech Solutions
  • 18.25. Medtronic plc
  • 18.26. Nipro Corporation
  • 18.27. Oracle Corporation
  • 18.28. Terumo Corporation
  • 18.29. WellSky Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD BANK MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD BANK MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD BANK MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD BANK MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD BANK MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD BANK MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLOOD BANK MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD BANK MARKET SIZE, BY CRYOPRECIPITATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD BANK MARKET SIZE, BY CRYOPRECIPITATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD BANK MARKET SIZE, BY CRYOPRECIPITATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD BANK MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD BANK MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD BANK MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD BANK MARKET SIZE, BY FRESH FROZEN PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD BANK MARKET SIZE, BY FRESH FROZEN PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD BANK MARKET SIZE, BY FRESH FROZEN PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD BANK MARKET SIZE, BY FROZEN PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD BANK MARKET SIZE, BY FROZEN PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD BANK MARKET SIZE, BY FROZEN PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD BANK MARKET SIZE, BY PLATELETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD BANK MARKET SIZE, BY PLATELETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD BANK MARKET SIZE, BY PLATELETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS PLATELETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS PLATELETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS PLATELETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD BANK MARKET SIZE, BY POOLED PLATELETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD BANK MARKET SIZE, BY POOLED PLATELETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD BANK MARKET SIZE, BY POOLED PLATELETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD BANK MARKET SIZE, BY LEUKOREDUCED RED BLOOD CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD BANK MARKET SIZE, BY LEUKOREDUCED RED BLOOD CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD BANK MARKET SIZE, BY LEUKOREDUCED RED BLOOD CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD BANK MARKET SIZE, BY WASHED RED BLOOD CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD BANK MARKET SIZE, BY WASHED RED BLOOD CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD BANK MARKET SIZE, BY WASHED RED BLOOD CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD BANK MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD BANK MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD BANK MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD BANK MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD BANK MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD BANK MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD BANK MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD BANK MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD BANK MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD BANK MARKET SIZE, BY TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD BANK MARKET SIZE, BY TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD BANK MARKET SIZE, BY TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD BANK MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD BANK MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD BANK MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD BANK MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD BANK MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD BANK MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD BANK MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD BANK MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD BANK MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD BANK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BLOOD BANK MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD BANK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. GCC BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 168. GCC BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. G7 BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 195. G7 BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 199. G7 BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 204. NATO BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 208. NATO BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)